SCHEMBL6938283

SCHEMBL6938283

Cc1ccc(S(=O)(=O)Oc2cccs2)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.45
NFE2L2 Q16236 1/20 0.45
CA12 O43570 1/20 0.45
CA2 P00918 1/20 0.45
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
GAA P10253 3/20 0.44
HTT P42858 2/20 0.44
RAB9A P51151 2/20 0.44
ESR1 P03372 1/20 0.44
ESR2 Q92731 1/20 0.44
NPC1 O15118 1/20 0.44
LMNA P02545 2/20 0.42
MAPK1 P28482 1/20 0.42
VDR P11473 1/20 0.41
ALDH1A1 P00352 4/20 0.41
MAPT P10636 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
PTGS2 P35354 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11320357 0.84 TDP1 (0.46) CA12CA2MEN1KMT2ARAB9A
SCHEMBL29004145 0.80 CA2 (0.46) CA2MEN1KMT2AHTTLMNA
SCHEMBL6690189 0.77 CA2 (0.46) KEAP1NFE2L2CA12CA2MEN1
SCHEMBL6939058 0.75 F2 (0.40) CA12CA2HTTALDH1A1SMN1; SMN2
SCHEMBL1418054 0.74 RAB9A (0.47) KMT2AHTTRAB9ANPC1LMNA
SCHEMBL28092304 0.74 TDP1 (0.38) CA2MEN1KMT2AGAAHTT
SCHEMBL10436860 0.73 ALDH1A1 (0.39) CA2HTTRAB9ANPC1ALDH1A1
SCHEMBL27418215 0.73 F2 (0.38) MEN1KMT2AHTTRAB9ANPC1
SCHEMBL21803201 0.72 RAB9A (0.49) MEN1KMT2AHTTRAB9ANPC1
SCHEMBL2480964 0.72 RAB9A (0.41) KEAP1NFE2L2CA12CA2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115326942-A Analytical method for measuring p-toluenesulfonic acid thiophene ester 苏州正济医药研究有限公司 2022-11-11 CN disclosed
EP-2750681-A1 BRANCHED DISCRETTE PEG CONSTRUCTS Quanta Biodesign, Ltd. (US) 2014-07-09 EP disclosed
WO-2013033476-A1 BRANCHED DISCRETTE PEG CONSTRUCTS QUANTA BIODESIGN, LTD. (US) 2013-03-07 WO disclosed
EP-1167372-B1 2,2-(Diaryl)vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst TAKASAGO PERFUMERY CO LTD (JP) 2003-12-10 EP disclosed
US-6455720-B1 AS CATALYSTS TAKASAGO INTERNATIONAL CORPORATION (JP) 2002-09-24 US disclosed
US-20020058837-A1 2,2 (Diarlyl) Vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst TAKASAGO INTERNATIONAL CORPORATION (JP) 2002-05-16 US disclosed
US-6365776-B1 FROM ORGANOHALOGEN COMPOUND AND AMINE USING PALLADIUM COMPOUND CATALYST AND PROMOTER TAKASAGO INTERNATIONAL CORPORATION (JP) 2002-04-02 US disclosed
US-20020035295-A1 PROCESS FOR PRODUCING AROMATIC AMINES TAKASAGO INTERNATIONAL CORPORATION 2002-03-21 US disclosed
EP-1167372-A1 2,2-(Diaryl)vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst Takasago International Corporation (JP) 2002-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035295-A1 PROCESS FOR PRODUCING AROMATIC AMINES TYR, DDC, PNMT KEAP1 559/4885NFE2L2 446/4885CA12 4037/4885
US-20020058837-A1 2,2 (Diarlyl) Vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst DDT, PDCD11, PLD2 KEAP1 468/4885NFE2L2 420/4885CA12 4431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.